PATENT CLAIM ANALYSIS

Application Number: 16025519
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["544", "279000"]

Abstract:
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

Claim (Index 106):
The method of  claim 94 , wherein the cancer is glioblastoma.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 95.0
- Lexical Diversity: 1.19355
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15408768', '15358371', '14256438', '14132653', '13915775']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7225830271873247
- 35 USC 102 Novelty (BERT): 0.5139234243320931
- Combined Prediction Score: 0.7017170669018016
- Mean Citation Score: 230.63026
- Max Citation Score: 238.27563
- Similarity Product: 142.65990567280232

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test